success rate with simple aspiration. Andrivet and colleagues concluded that thoracic drainage "via a chest tube was significantly more effective in the treatment of pneumothorax" than simple aspiration. 5 Our consensus panel was also aware of the unpublished British Thoracic Society (BTS) survey that Drs. Miller and Harvey mention in their letter. We did not believe, however, that approbation, noted in this survey, by British practitioners of the 1993 BTS pneumothorax guideline recommendations 6 for simple aspiration could substitute for investigative data. Moreover, two recent publications report that the majority of UK physicians do not conform to the 1993 BTS guidelines in managing patients with spontaneous pneumothorax. 7,8 We regret the description of the ACCP document as "biased." The 32 members of the expert panel were selected through an explicit methodology described in the statement and represent the leading published experts in this field. Also, the entire Delphi consensus panel, the ACCP Health and Science Policy Committee, and the Executive Committee of the ACCP Board of Regents reviewed, revised, and approved the statement before its publication. The writing committee responded to the minority concerns of Drs. Miller and Harvey by referring to the BTS guidelines in the published statement and by stating that "two panel members argued that simple aspiration is usually effective for stable patients." The consensus document could not do more to represent the opinions of a small minority of the expert panel without unjustifiably altering the majority consensus.
Low-Dose Spiral CT Screening
To the Editor:
I applaud Frederic W. Grannis, Jr., MD, for his views on the subject of lung cancer screening (February 2001). 1 As a lung cancer survivor, I have followed the debate over low-dose spiral CT screening closely and with great interest. I have been dismayed by the backlash against the Early Lung Cancer Action Project (ELCAP) study (and the ongoing research by the International Collaboration to Screen for Lung Cancer [ICScreen]), led by the National Cancer Institute (NCI), and by several physicians in the lung cancer field. I have read the numerous admonitions against jumping on the low-dose CT screening bandwagon. These cautionary tales have often been delivered in condescending tones aimed at those of us who can't possibly understand what good science entails, and why these studies are necessary. There is no doubt that a prospective, randomized, controlled trial would be the ideal study for evaluating low-dose spiral CT screening for lung cancer. There is no doubt that additional studies are needed to further characterize and quantify the risks involved in screening for lung cancer using low-dose spiral CT. What are the costs of waiting to pursue widespread screening research based on the ELCAP findings until a prospective trial such as the one proposed by the NCI can be completed? In answering this question, Dr. Grannis provides a context for this debate that has heretofore been missing, or at best, gratuitously acknowledged-that the devastation wrought by lung cancer is relevant. The high incidence and abysmally low survival rate associated with lung cancer is relevant. The fact that progress in preventing and treating lung cancer has occurred at a glacial pace (over decades) is relevant.
We know what the world looks like without low-dose spiral CT screening. The human toll and economic burden of lung cancer is enormous and unrelenting. I ask those lung cancer specialists who caution against moving forward until a prospective, randomized, controlled study can be conducted: just what world are you living in that affords you such a luxury? From my view, the ongoing ELCAP/ICScreen research deserves our full support.
Karen Parles, MLS Lung Cancer Online
Setauket, NY 
Pneumomediastinum Following Spirometry
Spirometry is a simple and common procedure performed to access pulmonary lung function. Complications from testing are rare but can include dizziness from hyperventilation, and vasovagal reactions. The development of pneumomediastinum following spirometric testing has also been previously reported in two normal subjects 1,2 and in one immunocompromised patient with presumed Pneumocystis carinii pneumonia. 3 Patients undergoing spirometry are instructed to take a deep inspiration to total lung capacity and then to expire vigorously. This causes a rapid increase in lung volume and pressure changes in the alveolus. These sudden changes in alveolar volume and transpulmonary pressure can lead to alveolar rupture and subsequent air entry into the bronchovascular sheath. 4 We report a 32-year-old white man who developed a pneumomediastinum after undergoing spirometry. The patient had a history of perennial allergic rhinosinusitis and had complained of vague and intermittent upper-chest tightness for several months. He denied any gastric reflux symptoms.
Spirometry was performed before and after administration of nebulized levalbuterol hydrochloride (0.63 mg) and findings were normal. Two hours later, he developed severe throat and neck pain. He also had a change in his voice to a high-pitched voice. Physical examination noted palpable crepitus in the neck. A high-resolution CT scan of the chest was obtained to excluded underlying parenchymal lung disease. The only abnormality was the pneumomediastinum (Fig 1) . All symptoms resolved within 36 h. The chest radiograph finding was normal 5 days later.
Although spirometry is a safe and useful test, one should be aware of the physiologic changes that occur in the respiratory tract with the vigorous straining required to complete the test. Furthermore, one should suspect pneumomediastinum as a complication if the patient complains of severe neck or throat pain following the procedure.
